$2.79
(Market cap
$17,453 Mln
Revenue (TTM)
$1,080 Mln
P/E Ratio
--
P/B Ratio
55.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-45.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-5.4
-
Debt to Equity
-8.3
-
Book Value
$--
-
EPS
$-3.4
-
Face value
--
-
Shares outstanding
132,599,929
8 Years Aggregate
CFO
$-1,175.65 Mln
EBITDA
$-2,054.71 Mln
Net Profit
$-2,047.36 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Guardant Health (GH)
| 29.1 | 39.0 | 48.6 | 166.3 | 52.6 | 1.3 | -- |
|
BSE Sensex
| -8.6 | 2.9 | 1.8 | -5.1 | 6.9 | 8.1 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Guardant Health (GH)
| 234.3 | 12.8 | -0.6 | -72.8 | -22.4 | 64.9 | 107.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Guardant Health (GH)
|
131.9 | 17,452.8 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 |
| 276.3 | 37,764.0 | 4,286.9 | 577.2 | 20.3 | 88.2 | 70.9 | 35.1 | |
| 231.7 | 14,299.5 | 867.5 | 506.6 | -0.6 | -- | 25 | 25.4 | |
| 52.0 | 13,354.5 | 2,375.5 | 833.4 | 41.5 | 40.7 | 17.6 | 6.9 | |
| 167.3 | 29,936.9 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 22.3 | 4.9 | |
| 505.9 | 11,084.5 | 1,132.5 | -309.4 | -25.0 | -52.9 | -- | 20.4 | |
| 457.0 | 13,347.1 | 2,678.3 | 460.4 | 21.3 | 103.2 | 29.4 | 22.3 | |
| 600.6 | 64,176.2 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 14.9 | 2.0 | |
| 540.1 | 23,174.2 | 3,169.8 | 1,287.4 | 51.3 | 20.6 | 20.2 | 3.9 | |
| 454.2 | 112,924.4 | 12,255.1 | 4,338.3 | 32.0 | 23.7 | 26.4 | 5.8 |
Shareholding Pattern
View DetailsAbout Guardant Health (GH)
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360... Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California. Read more
-
Co-Founder, Co-CEO & Chairman
Dr. Helmy Eltoukhy Ph.D.
-
Co-Founder, Co-CEO & Chairman
Dr. Helmy Eltoukhy Ph.D.
-
Headquarters
Palo Alto, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Guardant Health (GH)
What is the current share price of Guardant Health Inc (GH) Today?
The share price of Guardant Health Inc (GH) is $131.90 (NASDAQ) as of 18-Jun-2026 14:40 EDT. Guardant Health Inc (GH) has given a return of 52.64% in the last 3 years.
What is the current PB & PE ratio of Guardant Health Inc (GH)?
Since, TTM earnings of Guardant Health Inc (GH) is negative, P/E ratio is not available.
The P/B ratio of Guardant Health Inc (GH) is 55.67 times as on 12-Jun-2026, a 1245 premium to its peers’ median range of 4.14 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-30.67
|
-128.57
|
|
2024
|
-8.61
|
-26.91
|
|
2023
|
-6.32
|
19.09
|
|
2022
|
-4.24
|
46.10
|
|
2021
|
-24.90
|
15.66
|
What is the 52 Week High and Low of Guardant Health Inc (GH)?
The 52-week high and low of Guardant Health Inc (GH) are Rs 135.00 and Rs 40.36 as of 19-Jun-2026.
What is the market cap of Guardant Health Inc (GH)?
Guardant Health Inc (GH) has a market capitalisation of $ 17,453 Mln as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Guardant Health Inc (GH)?
Before investing in Guardant Health Inc (GH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.